COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.49
+1.38%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$32.03
From 52W high−26.49%
Volume2.23M
Market cap$5.46B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$32.03
From 52W high
−26.49%
Volume
2.23M
Market cap
$5.46B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.4x
P/E (TTM)
—
RSI (14)
46.5
MomentumView details →
1D Return
+1.38%
YTD Return
−13.78%
SummaryUpdated Jun 1, 2026
Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Unum Therapeutics Inc., the company underwent a strategic transformation and rebranded to Cogent Biosciences in October 2020. The company went public in March 2018 and focuses on developing precision therapies for genetically defined diseases, particularly targeting rare conditions with significant unmet medical needs.
Similar companies
Latest newsMore news →
The FDA accepted Cogent Biosciences' New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis, supported by positive results from the APEX pivotal trial.51d agoCogent Biosciences signed a five-year commercial supply agreement with Hovione FarmaCiencia S.A. for the purchase of bezuclastinib spray-dried dispersion and tablets, with automatic two-year renewals.63d agoCogent Biosciences reported a net loss of $96.4 million for Q2 2026, with research and development expenses of $70.8 million and general and administrative expenses of $31.8 million.87d ago